Neurosoft Bioelectronics, a neurotechnology company, has secured $7.5 million in seed funding to accelerate development of its minimally invasive brain-computer interface (BCI) platform.
The round was led by Skybound Venture Capital, with participation from PL Capital, IAG Capital Partners, Connecticut Innovations, and additional investors. With the latest raise, the company’s total funding now exceeds $20 million.
What The Company Does
Neurosoft Bioelectronics develops soft, flexible brain-computer interface technologies designed to improve neural data collection while reducing invasiveness compared to conventional implantable systems.
The company’s platform is based on proprietary stretchable electrode technology originally developed at EPFL. Unlike rigid implants that penetrate brain tissue, Neurosoft’s electrodes are designed to conform to the surface of the brain, enabling broader cortical access while minimising tissue disruption.
According to the company, this approach supports long-term integration with the body and allows for high-quality neural signal acquisition at scale. Its technology is being developed for applications involving neurological disorders and advanced neurointerface systems.
The platform has already been tested in 10 patients as the company advances clinical and technical validation.
Advertisement
Market Context / Industry Background
Brain-computer interface research has attracted growing investment in recent years as advances in neurotechnology, materials science, and AI improve the potential for direct neural communication systems. BCIs are increasingly being explored for medical applications including neurological rehabilitation, communication support, and treatment of motor and cognitive disorders.
One of the major technical challenges in the sector remains balancing signal quality with long-term safety and biocompatibility. Traditional rigid implants can create limitations around tissue compatibility and chronic implantation, leading researchers and companies to explore softer and less invasive alternatives.
At the same time, the development of large-scale neural datasets is becoming increasingly important as companies work toward AI-driven models capable of interpreting complex brain activity patterns.
Researchers are also focusing on improving the scalability and accessibility of brain-computer interface systems for broader clinical adoption. Advances in wireless communication, miniaturized electronics, and machine learning are enabling devices that can process neural signals more efficiently and with lower power consumption.
In parallel, regulatory agencies and healthcare providers are beginning to evaluate how these technologies could be integrated into long-term patient care. Several startups and research institutions are collaborating with hospitals to conduct early-stage clinical trials aimed at validating safety and therapeutic effectiveness. As investment in neurotechnology continues to expand globally, competition within the BCI sector is expected to intensify, particularly around data processing capabilities, implant design, and AI-driven interpretation of neural activity.
Founder / Investor Commentary
CEO and co-founder Nicolas Vachicouras said the company’s soft electrode platform provides access to neural data at a scale and quality that supports both clinical applications and future AI-driven neurotechnology systems.
“Our soft electrode platform, paired with a streamlined regulatory pathway, gives us access to neural data at a quality and scale no other approach can safely match today,” he said.
Vachicouras added that this neural data will contribute to the development of a cortical foundation model aimed at supporting the next generation of brain-computer interfaces and improving clinical outcomes over time.
Growth Plans / Use Of Funds
The newly raised funding will support continued development of Neurosoft’s minimally invasive BCI platform and accelerate work on its cortical foundation model.
The company plans to expand clinical validation efforts while advancing product development and regulatory activities. Investment will also support scaling of its neural data infrastructure and broader commercial preparation for future neurotechnology applications.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics is a neurotechnology company developing soft brain-computer interface systems for neurological applications. Founded in 2020 and originating from EPFL research, the company designs flexible implantable neural electrodes intended to improve long-term compatibility, neural data collection, and clinical outcomes in brain-interface technologies.
